Core Insights - Just - Evotec Biologics has entered a project agreement with BARDA to optimize biomanufacturing of antibodies against Ebola and related viruses, enhancing U.S. government response capabilities to hemorrhagic fever outbreaks [1][2] Group 1: Project Agreement Details - The multi-year program is valued at up to $10 million if all options are activated, aimed at developing cost-effective medical countermeasures for filovirus diseases [2] - The agreement includes a base period and two option periods, addressing the lack of approved treatments for Sudan virus infections [2] Group 2: Technological Approach - Just - Evotec Biologics will utilize its advanced biomanufacturing platform for molecular optimization, cell line development, and manufacturing process development for two antibodies identified in Ebola survivors [3] - The focus is on delivering high-yield, scalable, and cost-efficient production processes to support rapid deployment in public health emergencies [3] Group 3: Organizational Background - Just - Evotec Biologics is a subsidiary of Evotec SE, leveraging AI/ML technologies and advanced manufacturing strategies to accelerate biotherapeutics from discovery to commercial launch [7] - Evotec SE is a life science company that integrates breakthrough science with AI-driven innovation, focusing on drug discovery and development across various therapeutic areas [8]

Core Insights - Evotec has received a $10 million milestone payment from Bristol Myers Squibb (BMS) for the initiation of a Phase 1 clinical study of BMS-986506, a novel treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer [1][2] - This clinical study marks a significant advancement in the strategic collaboration between Evotec and BMS, focusing on protein degradation and the development of molecular glue candidates [2][3] Group 1: Clinical Development - The dosing of the first patient in the Phase 1 clinical trial signifies the transition of Evotec-BMS oncology platform into clinical evaluation [1][2] - BMS-986506 is a cereblon E3 ligase modulator developed under the strategic partnership, which aims to create new treatment paradigms in oncology [1][3] Group 2: Collaboration and Technology - The collaboration combines Evotec's PanOmics and PanHunter platforms with BMS's library of CELMoDs, aiming to identify novel molecular glue degraders for high-value oncology targets [3][6] - Evotec's drug discovery platform utilizes high-performance multi-omics screening and AI-enabled data analytics to selectively target and eliminate disease-driving proteins [2][7] Group 3: Molecular Glue Technology - Molecular glue degraders represent a new class of therapeutics that can induce interactions between E3 ubiquitin ligases and target proteins, leading to their degradation [5][6] - This mechanism significantly expands the range of druggable proteins, addressing the limitations of conventional small molecule therapeutics [4][5]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE regarding possible recovery of investor losses under federal securities laws following the company's recent financial disclosures [1][4]. Group 1: Investigation Details - The investigation focuses on whether Evotec's executive officers complied with federal securities laws after the company announced its "Horizon" restructuring initiative [1][4]. - Evotec projected revenue for fiscal year 2026 to be approximately €700 million to €780 million and adjusted EBITDA to be approximately €0 million to €40 million, indicating a transition year [3]. - The company expects total cash restructuring charges of approximately €100 million over the 2026–2028 period, along with non-cash components related to asset impairments [3]. Group 2: Investor Information - Investors who purchased Evotec securities and suffered losses are encouraged to join the investigation, with no cost or obligation [2]. - For further information, investors can contact Jim Baker at Johnson Fistel [2].

Core Viewpoint - Evotec SE is initiating a multistage transformation initiative named Horizon, which includes a strategic and financial framework to guide the company's future direction [3]. Group 1: Company Overview - The conference call features key executives from Evotec, including the CEO, CFO, and Chief People Officer, indicating a strong leadership presence for discussing strategic initiatives [2]. - The call is part of a broader effort to communicate with investors and analysts about the company's future plans and performance [2]. Group 2: Strategic Initiatives - The Horizon initiative represents the next phase in Evotec's transformation, suggesting a significant shift in the company's operational or strategic focus [3]. - The presentation aims to outline the associated strategic and financial framework, indicating a structured approach to the transformation process [3].

Core Viewpoint - Evotec SE is initiating a strategic transformation initiative named "Horizon" to reshape its operating model, enhance margins, and position itself for long-term growth in the drug discovery and preclinical development market [1][2]. Group 1: Strategic Transformation - The "Horizon" initiative builds on Evotec's previous "Priority Reset" and strategic roadmap established over the last two years [1]. - The transformation aims to position Evotec for stronger performance through 2027 and set the groundwork for further optimization and scaling towards 2030 [2]. Group 2: Organizational Changes - Evotec plans to simplify its organizational structure and consolidate expertise into new Centers of Excellence to enhance scientific collaboration and innovation [3]. - The company will reduce its global site footprint from 19 locations in 2024 to 10 sites over the next two years, affecting up to 800 positions [3]. Group 3: Financial Impact - The "Horizon" initiative is expected to generate approximately 75 million euros (around $87.3 million) in annual run-rate cost savings by 2027 [5]. - Restructuring-related cash charges are anticipated to be around 100 million euros between 2026 and 2028, along with potential non-cash impairment charges [5]. Group 4: Financial Outlook - Preliminary fiscal 2025 sales are projected at about 788 million euros, with adjusted EBITDA around 41 million euros, both within prior guidance [6]. - For 2026, revenue is expected to be between 700 million and 780 million euros, with adjusted EBITDA ranging from 0 to 40 million euros, indicating a transition year during restructuring [6]. - Long-term projections suggest revenues exceeding 1 billion euros between 2026 and 2030, with adjusted EBITDA margins expected to reach 20% by 2028 [7].

Evotec (NasdaqGS:EVO) Update / briefing March 10, 2026 10:00 AM ET Company ParticipantsChristian Wojczewski - CEOGabriele Hansen - Head of Global Communications and Investor RelationsPaul Hitchin - CFOConference Call ParticipantsCharles Weston - AnalystCharles Weston - AnalystFalko Friedrichs - Research AnalystRamakanth Swayampakula - Managing Director and Equity Research AnalystNone - AnalystGabriele HansenGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Gabriele ...

Operating Model Transformation to Accelerate Growth and Promote Agility Evotec SE, Horizon Webcast, March 2026 Today's Speakers Christian Wojczewski CEO Horizon Business Details Paul Hitchin CFO Horizon Financial Details Aurélie Dalbiez CPO Q&A Availability PAGE 2 Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection here with or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "ou ...

Core Insights - Moving iMage Technologies, Inc. has completed a significant cinema technology consultation and auditorium upgrade for EVO Entertainment's new eight-screen theater complex in Santa Fe, New Mexico, which opened on January 23, 2026 [1][2] Project Overview - The project involved the design, specification, and installation of advanced equipment including laser projectors, media servers, audio amplifiers, and loudspeakers to enhance the entertainment experience in each auditorium, particularly in the EVX® Enhanced Viewing Experience auditorium [2][11] - The upgraded theater complex serves as the anchor tenant within the newly renovated San Isidro Plaza [1] Company Collaboration - Ian Means, Director of Design and Architecture at EVO Entertainment, praised Moving iMage for their expertise, precision, and project management, highlighting their role as a trusted partner in delivering immersive experiences [5] - Moving iMage's President and COO, Francois Godfrey, expressed pride in the partnership with EVO Entertainment, emphasizing a shared commitment to enhancing guest experiences through next-generation technologies [5] Company Background - Moving iMage Technologies, founded in 2003, specializes in providing state-of-the-art out-of-home entertainment environments, offering products, integrated systems design, and installation services for various entertainment venues [7][8] - EVO Entertainment, a subsidiary of Elevate Entertainment Group, focuses on creating innovative entertainment destinations that include cinemas, bowling, games, and private event hosting [6]

Core Insights - Evotec SE is highlighted as a promising debt-free penny stock, particularly due to a recent grant from the Gates Foundation aimed at enhancing global access to biotherapeutics [1][2] - The grant is part of a broader initiative to improve the development and affordability of monoclonal antibodies, specifically targeting infectious diseases in low and middle-income countries [2] - Evotec is also set to benefit from Amgen's acquisition of Dark Blue Therapeutics, with potential proceeds from the transaction valued at up to $840 million, and Evotec holds a 20% equity stake in Dark Blue [3][4] Group 1 - The Gates Foundation grant will enable Evotec's subsidiary Just-Evotec Biologics to utilize its molecular design suite for biotherapeutics [1] - The goal of the grant is to make monoclonal antibodies more affordable and accessible in developing regions [2] - Evotec's involvement with Dark Blue includes a shareholding that allows it to receive a portion of the upfront payment from Amgen's acquisition [4] Group 2 - Evotec is recognized as a global life sciences company that focuses on drug discovery and development, utilizing advanced science, technology, and AI [4] - The company has a history of collaboration and investment in innovative projects, such as Dark Blue, which originated from its Academic BRIDGE portfolio [4]

Core Insights - Just - Evotec Biologics has received a grant from the Gates Foundation to enhance global access to biotherapeutics through its molecular design suite, J.MD™ [1] - The investment will support ten new projects focused on optimizing monoclonal antibodies (mAbs) over the next three years, targeting improvements in titer, pharmacokinetics, immunogenicity, and stability [1] - The initiative aims to reduce the cost of goods for mAbs, making them more affordable and accessible, particularly in low- and middle-income countries to combat infectious diseases [1] Investment and Development - The grant continues the support for selected Gates Foundation grantees, emphasizing the importance of developing cost-effective biotherapeutics [1] - The focus on molecular optimization is expected to enhance the developability of mAbs, which is crucial for their widespread use [1] - The collaboration with the Gates Foundation highlights the commitment to addressing global health challenges through innovative biotechnological solutions [1]